Osteoporosis is a degenerative disease that affects millions of dollars around the world. It is characterized by losses of bone bone quality, deterioration of micro -body structure and general decline in bone quality, which has led to an increase in fracture risk. With the age of the crowd, the incidence of osteoporosis has increased, and it is urgent to be effective. The current therapy, including anti -absorption and synthetic metabolic drugs, usually brings major side effects and prompts researchers to seek innovative solutions. The latest progress in biotechnology has opened up new ways for development therapies. These therapies may reverse the role of osteoporosis and enhance the effect of bone regeneration.
A recent study discussed the growth factor of the reorganized peptide, and the growth factor BB (RHPDGF-BB) derived from platelets (RHBMP7) and platelets was used to treat osteoporosis. The study was by Professor Mari Cleide Sogayar and Dr. Ana Claudia Carreira and his team, including MSC Thamar REIS, Dr. Alice Del Colletto, Dr. Luiz Si Lva, and Dr. Bruna Koga of Sao Paulo University. Researchers aims to study new synthetic metabolic treatment to promote the recovery of bone amount, especially for patients who cannot tolerate the current drugs.
The group uses the osteoporosis rats caused by ovarian resection to evaluate the impact of RHBMP7 and RHPDGF-BB’s whole body administration. Forty female Sprague Dawley rats underwent ovarian resection surgery, and when all animals show signs of osteoporosis, surgery began surgery. Treatment is administered in the vein.
Studies have found that the most effective treatment is to use RhpDGF-BB twice a week to combine with RHBMP-7, while RHBMP-7 twice a week. These treatment leads to a significant increase in bone volume score and the number of beams. Specifically, consolidated treatment has led to a significant increase in bone volume and bone number, and the separate treatment of BMP-7 has also led to significant improvement in these measures.
Professor SOGAYAR said: “Our discovery shows that in this animal model, the systemic administration of RHPDGF-BB and RHBMP-7 can partially reverse osteoporosis.” Potential candidates for clinical treatment.
The research team thoroughly analyzed the treated animals. Territic examination confirms the development of osteoporosis in ovarian removal in rats, which are characterized by significantly reduced thickness and increase in intramuscular fat cells. Effective treatment shows that the thickness of the small beams increases and the severity of the disease is reduced, indicating the potential treatment benefits.
The promising results of Professor SOGAYAR and Dr. Carreira’s research highlight the potential of RHPDGF-BB and RHBMP-7 as osteoporosis. The next step involves testing these treatments under clinical conditions to evaluate its effects in human patients. These discoveries have paved the road for the development of new synthetic metabolic therapies, which can significantly improve the current osteoporosis therapy of human beings.
Journal reference
Reis, TG, Del Colletto, AMS, Silva, LAS, KOGA, BAA, SOGAYAR, Carreira, ACO “reorganized human peptide growth factor, Bone protein 7 (RHBMP7) and platelet growth factor (RHPDGFFFFFFFFF)) was used for Ovarian removal of osteoporosis in the rats model. Doi: https: //doi.org/10.3390/biom14030317
About the author
Mari cleide sogayarPhD degree [email protected]
Born on June 3, 1943-a daughter, a son and four grandson
From 1961-1962, California California High School (Grade)
1963-1968 Biological Sciences, Institute of Biology, St. Paul University, Brazil
1971-1973, a master’s degree in biology at the University of California, California
1973-1977, the degree of biochemists at the Institute of Chemistry, St. Paulo University, Brazil
1980: Professor of Biochemistry Assistant Professor of Biochemistry, School of Chemistry, St. Paul University, Brazil
1982-1984: Dana Farber Institute of Cancer Institute Harvard Medical School, guest assistant professor
1987: Associate Professor and Associate Professor of Biochemical Biochemistry, School of Chemistry, St. Paul University, Brazil
2000: Full Professor of the Institute of Chemistry, Brazil-Biochemistry
2001-2013: The head of the core center of the cell and molecular biology (www.usp.br/nucel)
From 2013 to the present: the head of the core group of cells and molecular biology (www.usp.br/nucel)
About 50 doctoral degrees and consultants of 15 masters; about 30 POS-DOC supervisors
More than 200 articles, two books, and several books published
Seven patents stored in Brazil and the United States
Ana Claudia Oliveira Carreira NishiyamaDoctoral, [email protected]
ANA Claudia Oliveira Carreira is a researcher and educator who has rich experience in biotechnology and regeneration medicine. She is currently the assistant professor of Nature and Human Sciences (CCNH) of the Federal University (UFABC) of the Broadcasting Corporation. She also serves as a bachelor’s degree in biotechnology for the president of the undergraduate plan to build the core (NDE) president. UFABC has since since 2023. In addition, she is the permanent consultant of the graduate program of the UFABC PPG biological system, the anatomical structure (FMVZ/USP) of the family and wild animals of the PPG Veterinary College (FMVZ/USP), and it is also a study of the core core core core core core core core core core core core core core core core core core core core core core core core core Personnel group (medical school/USP).
Carreira has an outstanding academic background. Starting from her doctorate, this laid the foundation for her widespread research in organizational engineering and regeneration medicine. She has played a remarkable role in researchers and collaborators at St. Paul University and successfully coordinated several research projects. She has won many awards at the international conference. Dr. Carreira’s pioneering research includes the development and representation of cell animal tissues as innovative biomass materials, and exploring extracellular vesicles derived from stem cells for tissue repair and cancer treatment. In addition, her contribution to the growth factors of osteoporosis treatment of osteoporosis and the research on BMP (protein of osteophyte formation) have significant late medical science.
Dr. Carreira has been widely published. There are 77 articles in the peer review journal, writing two books, and contributing to multiple books chapters. She also has several patents related to biopharmaceuticals and regeneration therapy.
Carreira’s commitment to education and research has expanded to guidance to the next generation of scientists, and successfully supervised many master’s and doctoral students. She actively participated in international research cooperation and continued to advance her field through innovative research and academic contributions.
THAMARAGONvALVESRISMSC. ([email protected])
Born on February 23, 1996
2014-2018 Bachelor’s degree biotechnology, genetics and biochemistry, Institute of Genetics and Biochemistry, Uberlandia Federal University, Minas Gerais, Brazil
2018-2021 Master’s degree, interunit course biotechnology, Brazil St. Paulo University
2020-2023 R & D researchers, Biobreyer Reyneser Development LTD, St. Paul, Brazil
2023-R & D researcher at BioBreyer and Bioinsumos Brasil Research and Bioproducts Trade, St. Paul, Brazil
Published an article (REIS et al. 2024, biomolecular-DOI: 10.3390/biom1403031))
Alice Marcera Sanpa Delkito,PhD. ([email protected])
Born on February 11, 1996
2014-2017 Bachelor’s degree in biomedical science, Norv Dezhu Zhuhao University, St. Paul, Brazil.
2016-2018 Biomedical researcher in charge of the immunohistochemical department-hospital BP-Brazil St. Paul’s Beneficiênciaportuguesa.
2019-2023 Doctoral degree is anatomy of family and wildlife, the School of Veterinary and Animal Sciences from St. Paul University, Brazil.
2024-Lecturer at Estáciodesá, Brazil.
In 2024, associate researcher at Nunucel Group, Brazil.
Published an article (2024, biomolecules-DOI: 10.3390/biom1403031)
